Oncolog, Volume 36, Issue 03, July-September 1991

From cell culture to clinical protocol: In cancer research, the goals of scientist and clinician converge New clinic treats depressed cancer patients Half-century of progress in leukemia researchhttps://openworks.mdanderson.org/oncolog/1035/thumbnail.jp

OncoLog Volume 49, Number 05, May 2004

Experts Recommend Treating Cancer Pain in the Context of Other Symptoms Protocols: Studies Examine Treatment for Cancer-Related Pain Participation of Elderly Patients in Clinical Trials: Looking Beyond Age House Call: From Cancer Research to Clinical Practice DiaLog: The Next 20 Years: The Changing Face of Cancer Treatment, by Emil J. Freireich, MD, Director, Adult Leukemia Research Programhttps://openworks.mdanderson.org/oncolog/1129/thumbnail.jp

OncoLog, Volume 46, Number 01, January 2001

New Melanoma Staging System Reflects Key Prognostic Factors House Cell: Preventing Cancer: Food for Thought Educational Conferences Explore Issues Related to Cancer Care and Research DiaLog: Leukemia: Setting the Stage for Effective Treatments, by Emil J. Freireich, MD, Professor, Department of Leukemia Updated M. D. Anderson Website Designed to Meet the Online Needs of Patients and Physicianshttps://openworks.mdanderson.org/oncolog/1092/thumbnail.jp

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells

Arsenic trioxide (ATO) is an inorganic arsenic derivative that is very effective against acute promyelocytic leukemia. However, organic arsenic derivatives (OAD) have a more favorable toxicity profile than ATO. We herein characterized dipropil-S-glycerol arsenic (GMZ27), a novel OAD. GMZ27 had potent antiproliferative activity against human acute myeloid leukemia (AML) cell lines that was higher than that of ATO. In contrast to ATO, GMZ27 only marginally induced maturation of leukemia cells and had no effect on the cell cycle. The anti-leukemia activity of GMZ27 against AML cells was independent of the presence of the PML-RARα fusion protein. GMZ27 dissipates mitochondrial transmembrane potential, and induces cleavage of caspase 9 and activation of caspase 3 without altering the expression levels of (BCL-2), BAX and BCL-xl. GMZ27 induces the formation of intracellular superoxide, a reactive oxygen species (ROS) which plays a major role in the antileukemia activity of this OAD. In addition to ROS generation, GMZ27 concomitantly reduces intracellular glutathione which markedly weakens the cellular antioxidant capacity, thus enhancing the detrimental intracellular effects of ROS production. These results indicate that GMZ27 induces apoptosis in AML cells in a PML-RARα-independent fashion, through the induction of ROS production. This activity provides the rationale for the testing of GMZ27 in patients with AML

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

Comment in Lowering the High Cost of Cancer Drugs--III. [Mayo Clin Proc. 2016] Lowering the High Cost of Cancer Drugs--I. [Mayo Clin Proc. 2016] Lowering the High Cost of Cancer Drugs--IV. [Mayo Clin Proc. 2016] In Reply--Lowering the High Cost of Cancer Drugs. [Mayo Clin Proc. 2016] US oncologists call for government regulation to curb drug price rises. [BMJ. 2015